GSK3B and pancreatic neoplasm: Among GSK-3β inhibitors that are currently tested in clinical trials, 9-ING-41 was selected as it was recently granted fast-track designation for treatment of patients with pancreatic cancer by the U.S. Food and Drug Administration (FDA).